Prostate Cancer

>

Latest News

The Evolving Landscape of Prostate Cancer Management
The Evolving Landscape of Prostate Cancer Management

October 28th 2024

Maha Hussain, MD, FACP, FASCO, spoke about BRCA testing and ctDNA as diagnostic tools and PSMA-imaging and -targeted approaches in prostate cancer.

Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.
Darolutamide/ADT Improves rPFS in Metastatic HSPC

October 13th 2024

Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.
Apalutamide Significantly Improves OS Vs Enzalutamide in Metastatic CSPC

October 11th 2024

Detailed results from the phase 3 TALAPRO-2 trial will be submitted for presentation at a future medical meeting and shared with global health authorities.
Talazoparib/Enzalutamide Combo Prolongs Survival in Metastatic CRPC

October 10th 2024

Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.
Nivolumab/RT Improves Biochemical Recurrence Outcomes in Prostate Cancer

October 4th 2024

More News